NUS Medicine Researchers Uncover DUSP4's Role in CAR T Cell Efficacy
A study reveals that DUSP4 protein enhances CD8+ T cell function, potentially improving CAR T cell therapies for colorectal cancer.
DUSP4 sustains CD8+ T cell anti-tumor activity and prevents exhaustion.
Increased DUSP4 activity enhances CAR T cell proliferation and effectiveness.
Lower DUSP4 levels in colorectal cancer patients correlate with poorer survival rates.
Researchers at NUS Medicine have identified dual-specificity phosphatase 4 (DUSP4) as a crucial protein that helps maintain the anti-tumor activity of CD8+ T cells, which are vital for effective cancer immunotherapy. The study indicates that DUSP4 regulates the ERK2–KLF2 signaling pathway, thereby preventing T cell exhaustion, a condition that diminishes their ability to combat tumors. This discovery could lead to advancements in CAR T cell therapies for colorectal cancer.
The research team, led by experts from the Yong Loo Lin School of Medicine at the National University of Singapore, conducted a comprehensive analysis combining clinical data from colorectal cancer patients with laboratory experiments. They found that models deficient in DUSP4 exhibited larger tumors and weaker CD8+ T cell responses, highlighting the protein's role in sustaining immune cell functionality. Additionally, lower levels of DUSP4 were linked to reduced overall survival in colorectal cancer patients, underscoring its potential as a biomarker for treatment outcomes.
The study revealed that DUSP4 primarily supports the activity of immune cells rather than directly inhibiting tumor growth. The absence of DUSP4 in blood-forming cells led to diminished CD8+ T cell responses and increased tumor development, while its removal from cancer cells had minimal impact. The researchers discovered that DUSP4's regulation of the ERK2 and KLF2 signaling pathway is critical; insufficient DUSP4 leads to increased ERK2 activity, which in turn raises KLF2 levels, inhibiting the genetic programs necessary for CD8+ T cell function.
In laboratory experiments, the researchers utilized CRISPR activation to enhance DUSP4 activity in CAR T cells, resulting in improved proliferation and cancer-killing capabilities against colorectal cancer cells. The DUSP4-enhanced CAR T cells produced smaller tumors in preclinical models compared to standard CAR T cells, suggesting a promising strategy for enhancing T cell therapies in challenging tumor environments.
Looking ahead, the research team plans to explore how DUSP4 is regulated within tumors and identify additional molecules that influence T cell function. They aim to investigate methods to further increase DUSP4 activity in engineered immune cells. The ultimate goal is to leverage these findings to develop more effective T cell-based immunotherapies for colorectal cancer and other solid tumors.
